Identifying KRAS mutations in non-small cell lung cancer of Iraqi patients
Cancer Plus · 10.04.2026 · 8 (1) · 025330051
DOI: 10.36922/cp025330051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Plus, online erschienen am 10.04.2026. Verfasst von Mays Talib Abdallah.
Abstract (Originalsprache)
Lung cancer remains one of the most common malignancies. It is usually categorized into two types: small-cell lung cancer and non-small-cell lung cancer (NSCLC). Among the types of NSCLC, adenocarcinoma is the most common and is more prevalent in women than in men. The current study aims to identify KRAS mutations in a population with metastatic lung cancer. Moreover, the clinical significance of the KRAS mutations was also explored. For this purpose, KRAS status was evaluated by polymerase chain reaction and reverse hybridization. According to the molecular results, mutations were observed at codons 12, 13, 59, 61, 117, and 146. Interestingly, the number of patients with stage II disease was significantly higher, indicating that the type of KRAS alteration may be associated with early disease spread. Thus, these mutations were associated with poor responses to cetuximab and panitumumab, underscoring the important role of KRAS profiling in strategizing treatment modifications. We can also conclude that molecular diagnostics plays its role in everyday clinical practice by complementing precision oncology and improving the outlook for patients with NSCLC.
Zitieren
APA
Abdallah, M. T. (2026). Identifying KRAS mutations in non-small cell lung cancer of Iraqi patients. Cancer Plus, 8(1), 025330051. https://doi.org/10.36922/cp025330051
Vancouver
Abdallah MT. Identifying KRAS mutations in non-small cell lung cancer of Iraqi patients. Cancer Plus. 2026;8(1):025330051. doi:10.36922/cp025330051
BibTeX
@article{Abdallah2026,
author = {Abdallah, Mays Talib},
title = {Identifying KRAS mutations in non-small cell lung cancer of Iraqi patients},
journal = {Cancer Plus},
year = {2026},
volume = {8},
number = {1},
pages = {025330051},
doi = {10.36922/cp025330051}
}
EUVIMED